Sector consensus Attovia Therapeutics, Inc.
Stocks
ATTO
US04987L1026
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 12/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 22.79 USD | +1.15% |
|
-5.83% | - |
| 09-03 | Attovia Therapeutics Q2 Net Loss Widens | MT |
| 09-03 | Attovia Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | 42.2 | +87.31% | 5 | |||
| 187.07 | +21.08% | 18 | ||||||
| 1,170.7 | +17.64% | 15 | ||||||
| 200.18 | +57.28% | 22 | ||||||
| 49.74 | +22.33% | 24 | ||||||
| 102.47 | +23.63% | 20 | ||||||
| 2,453.79 | +17.8% | 15 | ||||||
| 1,397.26 | +5.85% | 8 | ||||||
| 618.43 | +30.36% | 18 | ||||||
| 53.69 | -6.52% | 16 | ||||||
| 21.57 | +71.84% | 13 | ||||||
| 678.06 | +27.19% | 16 | ||||||
| 110 | +32.91% | 12 | ||||||
| 134.69 | +68.06% | 21 | ||||||
| 109.9 | +49.28% | 20 | ||||||
| 109 | +85.06% | 9 | ||||||
| 12.75 | +65.16% | 4 | ||||||
| 100.18 | +57.11% | 16 | ||||||
| 120.08 | +35.36% | 13 | ||||||
| 228.89 | +30.74% | 9 | ||||||
| Average | 395.03 | +39.97% | 15 | ||||||
| Weighted average by Cap. | 519.06 | +30.38% | 16 |
- Stock Market
- Stocks
- ATTO Stock
- Sector Attovia Therapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
